Pulmonary fibrosis associated with rheumatoid arthritis: from pathophysiology to treatment strategies

References

• Aletaha D, Smolen JS. Diagnosis and management of rheumatoid arthritis: a review. JAMA. 2018;320:1360–1372.
   PubMed Web of Science ®Google Scholar
• Esposito AJ, Chu SG, Madan R, et al. Thoracic manifestations of rheumatoid arthritis. Clin Chest Med. 2019;40:545–560.
   PubMed Web of Science ®Google Scholar
• Spagnolo P, Lee JS, Sverzellati N, et al. The lung in rheumatoid arthritis: focus on interstitial lung disease. Arthritis Rheumatol. 2018;70:1544–1554.
   PubMed Web of Science ®Google Scholar
• Spagnolo P, Cordier J-F, Cottin V. Connective tissue diseases, multimorbidity and the ageing lung. Eur Respir J. 2016;47:1535–1558.
   PubMed Web of Science ®Google Scholar
• Turesson C, O’Fallon WM, Crowson CS, et al. Extra-articular disease manifestations in rheumatoid arthritis: incidence trends and risk factors over 46 years. Ann Rheum Dis. 2003;62:722–727.
   PubMed Web of Science ®Google Scholar
• Bongartz T, Nannini C, and Medina-Velasquez YF, et al. Incidence and mortality of interstitial lung disease in rheumatoid arthritis: a population-based study. Arthritis Rheum. 2010;62:1583–1591 .
   PubMed Web of Science ®Google Scholar
• Gochuico BR, Avila NA, Chow CK, et al. Progressive preclinical interstitial lung disease in rheumatoid arthritis. Arch Intern Med. 2008;168:159–166.
   PubMedGoogle Scholar
• England BR, Hershberger D. Management issues in rheumatoid arthritis-associated interstitial lung disease. Curr Opin Rheumatol. 2020;32:255–263.
   PubMedGoogle Scholar
• Kim D, Cho S-K, Choi C-B, et al. Impact of interstitial lung disease on mortality of patients with rheumatoid arthritis. Rheumatol Int. 2017;37:1735–1745.
   PubMed Web of Science ®Google Scholar
• Kelly CA, Saravanan V, Nisar M, et al. Rheumatoid arthritis-related interstitial lung disease: associations, prognostic factors and physiological and radiological characteristics–a large multicentre UK study. Rheumatology (Oxford). 2014;53:1676–1682.
   PubMed Web of Science ®Google Scholar
• Bilgici A, Ulusoy H, Kuru O, et al. Pulmonary involvement in rheumatoid arthritis. Rheumatol Int. 2005;25:429–435.
   PubMed Web of Science ®Google Scholar
• Tyker A, Ventura IB, Lee CT, et al. High-titer rheumatoid factor seropositivity predicts mediastinal lymphadenopathy and mortality in rheumatoid arthritis-related interstitial lung disease. Sci Rep. 2021;11:22821.
   PubMedGoogle Scholar
• Saag KG, Kolluri S, Koehnke RK. Rheumatoid arthritis lung disease. Determinants of radiographic and physiologic abnormalities. Arthritis Rheum. 1996;39:1711–1719.
   PubMed Web of Science ®Google Scholar
• Koduri G, Norton S, Young A, et al. Interstitial lung disease has a poor prognosis in rheumatoid arthritis: results from an inception cohort. Rheumatology (Oxford). 2010;49:1483–1489.
   PubMed Web of Science ®Google Scholar
• Natalini JG, Baker JF, Singh N, et al. Autoantibody seropositivity and risk for interstitial lung disease in a prospective male-predominant rheumatoid arthritis cohort of U.S. Veterans. Ann Am Thorac Soc. 2021;18:598–605.
   PubMedGoogle Scholar
• Sparks JA, Jin Y, Cho S-K, et al. Prevalence, incidence and cause-specific mortality of rheumatoid arthritis-associated interstitial lung disease among older rheumatoid arthritis patients. Rheumatology (Oxford). 2021;60:3689–3698.
   PubMed Web of Science ®Google Scholar
• Assayag D, Elicker BM, Urbania TH, et al. Rheumatoid arthritis-associated interstitial lung disease: radiologic identification of usual interstitial pneumonia pattern. Radiology. 2014;270:583–588.
   PubMedGoogle Scholar
• Kim EJ, Elicker BM, and Maldonado F, et al. Usual interstitial pneumonia in rheumatoid arthritis-associated interstitial lung disease. Eur Respir J. 2010;35:1322–1328 .
   PubMed Web of Science ®Google Scholar
• Lee H-K, Kim DS, and Yoo B, et al. Histopathologic pattern and clinical features of rheumatoid arthritis-associated interstitial lung disease. Chest. 2005;127:2019–2027 .
   PubMed Web of Science ®Google Scholar
• Raghu G, Remy-Jardin M, Myers JL, et al. Diagnosis of idiopathic pulmonary fibrosis. An official ATS/ERS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med. 2018;198. e44–e68.
   PubMed Web of Science ®Google Scholar
• Mohning MP, Amigues I, Demoruelle MK, et al. Duration of rheumatoid arthritis and the risk of developing interstitial lung disease. ERJ Open Res. 2021;7:00633–02020.
   PubMedGoogle Scholar
• Mena-Vázquez N, Rojas-Gimenez M, Romero-Barco CM, et al. Predictors of progression and mortality in patients with prevalent rheumatoid arthritis and interstitial lung disease: a Prospective Cohort Study. J Clin Med. 2021;10:874.
   PubMedGoogle Scholar
• Luppi F, Sebastiani M, Salvarani C, et al. Acute exacerbation of interstitial lung disease associated with rheumatic disease. Nat Rev Rheumatol. 2022;18:85–96.
   PubMed Web of Science ®Google Scholar
• Izuka S, Yamashita H, Iba A, et al. Acute exacerbation of rheumatoid arthritis-associated interstitial lung disease: clinical features and prognosis. Rheumatology (Oxford). 2021;60:2348–2354.
   PubMedGoogle Scholar
• Kreuter M, Koegler H, Trampisch M, et al. Differing severities of acute exacerbations of idiopathic pulmonary fibrosis (IPF): insights from the INPULSIS® trials. Respir Res. 2019;20:71.
   PubMedGoogle Scholar
• Deighton CM, Walker DJ, Griffiths ID, et al. The contribution of HLA to rheumatoid arthritis. Clin Genet. 1989;36:178–182.
   PubMed Web of Science ®Google Scholar
• MacGregor AJ, Snieder H, Rigby AS, et al. Characterizing the quantitative genetic contribution to rheumatoid arthritis using data from twins. Arthritis Rheum. 2000;43:30–37.
   PubMed Web of Science ®Google Scholar
• Huizinga TWJ, Amos CI, van der Helm-van Mil AHM, et al. Refining the complex rheumatoid arthritis phenotype based on specificity of the HLA-DRB1 shared epitope for antibodies to citrullinated proteins. Arthritis Rheum. 2005;52:3433–3438.
   PubMed Web of Science ®Google Scholar
• van der Helm-van Mil AHM, Huizinga TWJ, Schreuder TWJ, et al. An independent role of protective HLA class II alleles in rheumatoid arthritis severity and susceptibility. Arthritis Rheum. 2005;52:2637–2644.
   PubMed Web of Science ®Google Scholar
• Begovich AB, Carlton VEH, Honigberg LA, et al. A missense single-nucleotide polymorphism in a gene encoding a protein tyrosine phosphatase (PTPN22) is associated with rheumatoid arthritis. Am J Hum Genet. 2004;75:330–337.
   PubMed Web of Science ®Google Scholar
• Suzuki A, Yamada R, Chang X, et al. Functional haplotypes of PADI4, encoding citrullinating enzyme peptidylarginine deiminase 4, are associated with rheumatoid arthritis. Nat Genet. 2003;34:395–402.
   PubMed Web of Science ®Google Scholar
• Rodríguez MR, Núñez-Roldán A, Aguilar F, et al. Association of the CTLA4 3’ untranslated region polymorphism with the susceptibility to rheumatoid arthritis. Hum Immunol. 2002;63:76–81.
   PubMedGoogle Scholar
• Juge P-A, Lee JS, and Ebstein E, et al. MUC5B promoter variant and rheumatoid arthritis with interstitial lung disease. N Engl J Med. 2018;379:2209–2219 .
   PubMed Web of Science ®Google Scholar
• Peljto AL, Zhang Y, Fingerlin TE, et al. Association between the MUC5B promoter polymorphism and survival in patients with idiopathic pulmonary fibrosis. JAMA. 2013;309:2232–2239.
   PubMed Web of Science ®Google Scholar
• Juge P-A, Solomon JJ, van Moorsel CHM, et al. MUC5B promoter variant rs35705950 and rheumatoid arthritis associated interstitial lung disease survival and progression. Semin Arthritis Rheum. 2021;51:996–1004.
   PubMedGoogle Scholar
• Newton CA, Oldham JM, Ley B, et al. Telomere length and genetic variant associations with interstitial lung disease progression and survival. Eur Respir J. 2019;53:1801641.
   PubMedGoogle Scholar
• Jönsson E, Ljung L, Norrman E, et al. Pulmonary fibrosis in relation to genetic loci in an inception cohort of patients with early rheumatoid arthritis from Northern Sweden. Rheumatology (Oxford). 2022:61:943–952.
   PubMedGoogle Scholar
• Song ST, Kim SS, Kim JY, et al. Association of single nucleotide polymorphisms of PADI4 and HLA-DRB1 alleles with susceptibility to rheumatoid arthritis-related lung diseases. Lung. 2016;194:745–753.
   PubMed Web of Science ®Google Scholar
• Furukawa H, Oka S, Shimada K, et al. Association of human leukocyte antigen with interstitial lung disease in rheumatoid arthritis: a protective role for shared epitope. PLoS One. 2012;7:e33133.
   PubMed Web of Science ®Google Scholar
• Restrepo JF, Del Rincón I, Battafarano DF, et al. Clinical and laboratory factors associated with interstitial lung disease in rheumatoid arthritis. Clin Rheumatol. 2015;34:1529–1536.
   PubMed Web of Science ®Google Scholar
• Armanios MY, Chen JJ-L, Cogan JD, et al. Telomerase mutations in families with idiopathic pulmonary fibrosis. N Engl J Med. 2007;356:1317–1326.
   PubMed Web of Science ®Google Scholar
• Juge P-A, Borie R, Kannengiesser C, et al. Shared genetic predisposition in rheumatoid arthritis-interstitial lung disease and familial pulmonary fibrosis. Eur Respir J. 2017;49:1602314.
   PubMed Web of Science ®Google Scholar
• Stuart BD, Lee JS, Kozlitina J, et al. Effect of telomere length on survival in patients with idiopathic pulmonary fibrosis: an observational cohort study with independent validation. Lancet Respir Med. 2014;2:557–565.
   PubMed Web of Science ®Google Scholar
• Snetselaar R, van Moorsel CHM, Kazemier KM, et al. Telomere length in interstitial lung diseases. Chest. 2015;148:1011–1018.
   PubMed Web of Science ®Google Scholar
• Newton CA, Batra K, Torrealba J, et al. Telomere-related lung fibrosis is diagnostically heterogeneous but uniformly progressive. Eur Respir J. 2016;48:1710–1720.
   PubMed Web of Science ®Google Scholar
• Fujisaki M, Sugawara K. Properties of peptidylarginine deiminase from the epidermis of newborn rats. J Biochem. 1981;89:257–263.
   PubMedGoogle Scholar
• Bongartz T, Cantaert T, Atkins SR. Citrullination in extra-articular manifestations of rheumatoid arthritis. Rheumatology (Oxford). 2007;46:70–75.
   PubMed Web of Science ®Google Scholar
• Samara KD, Trachalaki A, Tsitoura E, et al. Upregulation of citrullination pathway: from Autoimmune to Idiopathic Lung Fibrosis. Respir Res. 2017;18:218.
   PubMedGoogle Scholar
• Giles JT, Darrah E, Danoff S, et al. Association of cross-reactive antibodies targeting peptidyl-arginine deiminase 3 and 4 with rheumatoid arthritis-associated interstitial lung disease. PLoS One. 2014;9:e98794.
   PubMed Web of Science ®Google Scholar
• Suzuki M, Ikari J, Anazawa R, et al. PAD4 deficiency improves bleomycin-induced neutrophil extracellular traps and fibrosis in mouse lung. Am J Respir Cell Mol Biol. 2020;63:806–818.
   PubMedGoogle Scholar
• Wang D, Zhang J, Lau J, et al. Mechanisms of lung disease development in rheumatoid arthritis. Nat Rev Rheumatol. 2019;15:581–596.
   PubMed Web of Science ®Google Scholar
• Paulin F, Doyle TJ, Fletcher EA, et al. Rheumatoid Arthritis-Associated Interstitial Lung Disease and idiopathic pulmonary fibrosis: shared mechanistic and phenotypic traits suggest overlapping disease mechanisms. Rev Invest Clin. 2015;67:280–286.
   PubMedGoogle Scholar
• Fischer A, Solomon JJ, du Bois RM, et al. Lung disease with anti-CCP antibodies but not rheumatoid arthritis or connective tissue disease. Respir Med. 2012;106:1040–1047.
   PubMed Web of Science ®Google Scholar
• Thiele GM, Tuma DJ, Willis MS, et al. Soluble proteins modified with acetaldehyde and malondialdehyde are immunogenic in the absence of adjuvant. Alcohol Clin Exp Res. 1998;22:1731–1739.
   PubMed Web of Science ®Google Scholar
• England BR, Duryee MJ, Roul P, et al. Malondialdehyde-Acetaldehyde adducts and antibody responses in rheumatoid arthritis-associated interstitial lung disease. Arthritis Rheumatol. 2019;71:1483–1493.
   PubMed Web of Science ®Google Scholar
• Thiele GM, Duryee MJ, Anderson DR, et al. Malondialdehyde-acetaldehyde adducts and anti-malondialdehyde-acetaldehyde antibodies in rheumatoid arthritis. Arthritis Rheumatol. 2015;67:645–655.
   PubMed Web of Science ®Google Scholar
• Mikuls TR, Gaurav R, Thiele GM, et al. The impact of airborne endotoxin exposure on rheumatoid arthritis-related joint damage, autoantigen expression, autoimmunity, and lung disease. Int Immunopharmacol. 2021;100:108069.
   PubMed Web of Science ®Google Scholar
• Yoshinouchi T, Ohtsuki Y, Ueda R, et al. Myofibroblasts and S-100 protein positive cells in idiopathic pulmonary fibrosis and rheumatoid arthritis-associated interstitial pneumonia. Eur Respir J. 1999;14:579–584.
   PubMedGoogle Scholar
• Turesson C, Matteson EL, Colby TV, et al. Increased CD4+ T cell infiltrates in rheumatoid arthritis-associated interstitial pneumonitis compared with idiopathic interstitial pneumonitis. Arthritis Rheum. 2005;52:73–79.
   PubMed Web of Science ®Google Scholar
• Atkins SR, Turesson C, Myers JL, et al. Morphologic and quantitative assessment of CD20+ B cell infiltrates in rheumatoid arthritis-associated nonspecific interstitial pneumonia and usual interstitial pneumonia. Arthritis Rheum. 2006;54:635–641.
   PubMed Web of Science ®Google Scholar
• Rangel-Moreno J, Hartson L, Navarro C, et al. Inducible bronchus-associated lymphoid tissue (iBALT) in patients with pulmonary complications of rheumatoid arthritis. J Clin Invest. 2006;116:3183–3194.
   PubMed Web of Science ®Google Scholar
• Menon M, Hussell T, Ali Shuwa H, et al. Regulatory B cells in respiratory health and diseases. Immunol Rev. 2021;299:61–73.
   PubMedGoogle Scholar
• Flores-Borja F, Bosma A, Ng D, et al. CD19+CD24hiCD38hi B cells maintain regulatory T cells while limiting TH1 and TH17 differentiation. Sci Transl Med. 2013;5:173ra23.
   PubMed Web of Science ®Google Scholar
• Ma L, Liu B, Jiang Z, et al. Reduced numbers of regulatory B cells are negatively correlated with disease activity in patients with new-onset rheumatoid arthritis. Clin Rheumatol. 2014;33:187–195.
   PubMedGoogle Scholar
• Atkins SR, Matteson EL, Myers JL, et al. Morphological and quantitative assessment of mast cells in rheumatoid arthritis associated non-specific interstitial pneumonia and usual interstitial pneumonia. Ann Rheum Dis. 2006;65:677–680.
   PubMedGoogle Scholar
• Distler JHW, Györfi A-H, Ramanujam M, et al. Shared and distinct mechanisms of fibrosis. Nat Rev Rheumatol. 2019;15:705–730.
   PubMed Web of Science ®Google Scholar
• Hasan SA, Eksteen B, Reid D, et al. Role of IL-17A and neutrophils in fibrosis in experimental hypersensitivity pneumonitis. J Allergy Clin Immunol. 2013;131:1663–1673.
   PubMedGoogle Scholar
• Zhang J, Wang D, Wang L, et al. Profibrotic effect of IL-17A and elevated IL-17RA in idiopathic pulmonary fibrosis and rheumatoid arthritis-associated lung disease support a direct role for IL-17A/IL-17RA in human fibrotic interstitial lung disease. Am J Physiol Lung Cell Mol Physiol. 2019;316:L487–L497.
   PubMedGoogle Scholar
• Yuan H, Jiao L, Yu N, et al. Histone deacetylase 3-mediated inhibition of microRNA-19a-3p facilitates the development of rheumatoid arthritis-associated interstitial lung disease. Front Physiol. 2020;11:549656.
   PubMed Web of Science ®Google Scholar
• Zhang C, Wang S, Lau J, et al. IL-23 amplifies the epithelial-mesenchymal transition of mechanically conditioned alveolar epithelial cells in rheumatoid arthritis-associated interstitial lung disease through mTOR/S6 signaling. Am J Physiol Lung Cell Mol Physiol. 2021;321:L1006–L1022.
   PubMedGoogle Scholar
• Murray LA, Argentieri RL, Farrell FX, et al. Hyper-responsiveness of IPF/UIP fibroblasts: interplay between TGFbeta1, IL-13 and CCL2. Int J Biochem Cell Biol. 2008;40:2174–2182.
   PubMed Web of Science ®Google Scholar
• Hussein MS, El-Barbary AM, Nada DW, et al. Identification of serum interleukin-13 and interleukin-13 receptor subunit expressions: rheumatoid arthritis-associated interstitial lung disease. Int J Rheum Dis. 2021;24:591–598.
   PubMedGoogle Scholar
• Shen H, Xia L, Lu J, et al. Interleukin-4 in rheumatoid arthritis patients with interstitial lung disease: a pilot study. Indian J Med Res. 2013;138:919–921.
   PubMed Web of Science ®Google Scholar
• Ma Z, Yu R, Zhu Q, et al. CXCL16/CXCR6 axis promotes bleomycin-induced fibrotic process in MRC-5 cells via the PI3K/AKT/FOXO3a pathway. Int Immunopharmacol. 2020;81:106035.
   PubMedGoogle Scholar
• Nusse R, Clevers H. Wnt/β-Catenin signaling, disease, and emerging therapeutic modalities. Cell. 2017;169:985–999.
   PubMed Web of Science ®Google Scholar
• Lim X, Nusse R. Wnt signaling in skin development, homeostasis, and disease. Cold Spring Harb Perspect Biol. 2013;5:a008029.
   PubMedGoogle Scholar
• Meuten T, Hickey A, Franklin K, et al. WNT7B in fibroblastic foci of idiopathic pulmonary fibrosis. Respir Res. 2012;13:62.
   PubMedGoogle Scholar
• Newman DR, Sills WS, Hanrahan K, et al. Expression of WNT5A in idiopathic pulmonary fibrosis and its control by TGF-β and WNT7B in human lung fibroblasts. J Histochem Cytochem. 2016;64:99–111.
   PubMed Web of Science ®Google Scholar
• Martin-Medina A, Lehmann M, Burgy O, et al. Increased extracellular vesicles mediate WNT5A signaling in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2018;198:1527–1538.
   PubMed Web of Science ®Google Scholar
• Yu M, Guo Y, Zhang P, et al. Increased circulating Wnt5a protein in patients with rheumatoid arthritis-associated interstitial pneumonia (RA-ILD). Immunobiology. 2019;224:551–559.
   PubMedGoogle Scholar
• Song JW, Do KH, Jang SJ, et al. Blood biomarkers MMP-7 and SP-A: predictors of outcome in idiopathic pulmonary fibrosis. Chest. 2013;143:1422–1429.
   PubMed Web of Science ®Google Scholar
• Prasse A, Probst C, Bargagli E, et al. Serum CC-chemokine ligand 18 concentration predicts outcome in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2009;179:717–723.
   PubMed Web of Science ®Google Scholar
• Greene KE, King TE, Kuroki Y, et al. Serum surfactant proteins-A and -D as biomarkers in idiopathic pulmonary fibrosis. Eur Respir J. 2002;19:439–446.
   PubMed Web of Science ®Google Scholar
• Chen J, Doyle TJ, Liu Y, et al. Biomarkers of rheumatoid arthritis-associated interstitial lung disease. Arthritis Rheumatol. 2015;67:28–38.
   PubMed Web of Science ®Google Scholar
• Doyle TJ, Patel AS, Hatabu H, et al. Detection of rheumatoid arthritis-interstitial lung disease is enhanced by serum biomarkers. Am J Respir Crit Care Med. 2015;191:1403–1412.
   PubMed Web of Science ®Google Scholar
• Shaw M, Collins BF, Ho LA, et al. Rheumatoid arthritis-associated lung disease. Eur Respir Rev. 2015;24:1–16.
   PubMedGoogle Scholar
• Rajasekaran A, Shovlin D, Saravanan V, et al. Interstitial lung disease in patients with rheumatoid arthritis: comparison with cryptogenic fibrosing alveolitis over 5 years. J Rheumatol. 2006;33:1250–1253.
   PubMedGoogle Scholar
• Pappas DA, Giles JT, Connors G, et al. Respiratory symptoms and disease characteristics as predictors of pulmonary function abnormalities in patients with rheumatoid arthritis: an observational cohort study. Arthritis Res Ther. 2010;12:R104.
   PubMedGoogle Scholar
• Dawson JK, Fewins HE, Desmond J, et al. Fibrosing alveolitis in patients with rheumatoid arthritis as assessed by high resolution computed tomography, chest radiography, and pulmonary function tests. Thorax. 2001;56:622–627.
   PubMed Web of Science ®Google Scholar
• Tanaka N, Kim JS, Newell JD, et al. Rheumatoid arthritis-related lung diseases: CT findings. Radiology. 2004;232:81–91.
   PubMed Web of Science ®Google Scholar
• Nurmi HM, Kettunen H-P, Suoranta S-K, et al. Several high-resolution computed tomography findings associate with survival and clinical features in rheumatoid arthritis-associated interstitial lung disease. Respir Med. 2018;134:24–30.
   PubMed Web of Science ®Google Scholar
• Travis WD, Costabel U, Hansell DM, et al. An official American Thoracic Society/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med. 2013;188:733–748.
   PubMed Web of Science ®Google Scholar
• Solomon JJ, Ryu JH, Tazelaar HD, et al. Fibrosing interstitial pneumonia predicts survival in patients with rheumatoid arthritis-associated interstitial lung disease (RA-ILD). Respir Med. 2013;107:1247–1252.
   PubMed Web of Science ®Google Scholar
• Kim EJ, Collard HR, King TE. Rheumatoid arthritis-associated interstitial lung disease: the relevance of histopathologic and radiographic pattern. Chest. 2009;136:1397–1405.
   PubMed Web of Science ®Google Scholar
• Flaherty KR, Colby TV, Travis WD, et al.Fibroblastic foci in usual interstitial pneumonia: idiopathic versus collagen vascular disease. Am J Respir Crit Care Med. 2003;167:1410–1415.
   PubMed Web of Science ®Google Scholar
• Nakamura Y, Suda T, Kaida Y, et al. Rheumatoid lung disease: prognostic analysis of 54 biopsy-proven cases. Respir Med. 2012;106:1164–1169.
   PubMed Web of Science ®Google Scholar
• Travis WD, Hunninghake G, King TE, et al. Idiopathic nonspecific interstitial pneumonia: report of an American Thoracic Society project. Am J Respir Crit Care Med. 2008;177:1338–1347.
   PubMed Web of Science ®Google Scholar
• Leslie KO, Trahan S, Gruden J. Pulmonary pathology of the rheumatic diseases. Semin Respir Crit Care Med. 2007;28:369–378.
   PubMed Web of Science ®Google Scholar
• Tsuchiya Y, Takayanagi N, Sugiura H, et al. Lung diseases directly associated with rheumatoid arthritis and their relationship to outcome. Eur Respir J. 2011;37:1411–1417.
   PubMed Web of Science ®Google Scholar
• Hyldgaard C, Hilberg O, and Pedersen AB, et al. A population-based cohort study of rheumatoid arthritis-associated interstitial lung disease: comorbidity and mortality. Ann Rheum Dis. 2017;76:1700–1706 .
   PubMed Web of Science ®Google Scholar
• Hyldgaard C, Ellingsen T, Hilberg O, et al. Rheumatoid arthritis-associated interstitial lung disease: clinical characteristics and predictors of mortality. Respiration. 2019;98:455–460.
   PubMed Web of Science ®Google Scholar
• Crowson CS, Rollefstad S, Ikdahl E, et al. Impact of risk factors associated with cardiovascular outcomes in patients with rheumatoid arthritis. Ann Rheum Dis. 2018;77:48–54.
   PubMed Web of Science ®Google Scholar
• Lee Y-K, Ahn GY, Lee J, et al. Excess mortality persists in patients with rheumatoid arthritis. Int J Rheum Dis. 2021;24:364–372.
   PubMedGoogle Scholar
• Zamora-Legoff JA, Krause ML, Crowson CS, et al. Patterns of interstitial lung disease and mortality in rheumatoid arthritis. Rheumatology (Oxford). 2017;56:344–350.
   PubMed Web of Science ®Google Scholar
• Goldin JG, Kim GHJ, Tseng C-H, et al. Longitudinal changes in quantitative interstitial lung disease on computed tomography after immunosuppression in the Scleroderma Lung Study II. Ann Am Thorac Soc. 2018;15:1286–1295.
   PubMed Web of Science ®Google Scholar
• Alevizos MK, Danoff SK, Pappas DA, et al. Assessing predictors of rheumatoid arthritis associated interstitial lung disease using quantitative lung densitometry. Rheumatology (Oxford). 2021. DOI: https://doi.org/10.1093/rheumatology/keab828. keab828.
   Google Scholar
• Solomon JJ, Chung JH, Cosgrove GP, et al. Predictors of mortality in rheumatoid arthritis-associated interstitial lung disease. Eur Respir J. 2016;47:588–596.
   PubMed Web of Science ®Google Scholar
• Jeganathan N, Nguyen E, Sathananthan M. Rheumatoid arthritis and associated interstitial lung disease: mortality rates and trends. Ann Am Thorac Soc. 2021;18:1970–1977.
   PubMedGoogle Scholar
• Fischer A, Brown KK, Du Bois RM, et al. Mycophenolate mofetil improves lung function in connective tissue disease-associated interstitial lung disease. J Rheumatol. 2013;40:640–646.
   PubMed Web of Science ®Google Scholar
• Cassone G, Manfredi A, Vacchi C, et al. Treatment of rheumatoid arthritis-associated interstitial lung disease: lights and shadows. J Clin Med. 2020;9:E1082.
   PubMed Web of Science ®Google Scholar
• Yamakawa H, Ogura T, Kameda H, et al. Decision-Making strategy for the treatment of rheumatoid arthritis-associated interstitial lung disease (RA-ILD). J Clin Med. 2021;10:3806.
   PubMedGoogle Scholar
• Hoes JN, Jacobs JWG, Boers M, et al. EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis. 2007;66:1560–1567.
   PubMed Web of Science ®Google Scholar
• Kelly CA, Nisar M, Arthanari S, et al. Rheumatoid arthritis related interstitial lung disease - improving outcomes over 25 years: a large multicentre UK study. Rheumatology (Oxford). 2021;60:1882–1890.
   PubMedGoogle Scholar
• Oldham JM, Lee C, Valenzi E, et al. Azathioprine response in patients with fibrotic connective tissue disease-associated interstitial lung disease. Respir Med. 2016;121:117–122.
   PubMed Web of Science ®Google Scholar
• Fui A, Bergantini L, Selvi E, et al. Rituximab therapy in interstitial lung disease associated with rheumatoid arthritis. Intern Med J. 2020;50:330–336.
   PubMedGoogle Scholar
• Robles-Perez A, Dorca J, Castellví I, et al. Rituximab effect in severe progressive connective tissue disease-related lung disease: preliminary data. Rheumatol Int. 2020;40:719–726.
   PubMed Web of Science ®Google Scholar
• Vadillo C, Nieto MA, Romero-Bueno F, et al. Efficacy of rituximab in slowing down progression of rheumatoid arthritis-related interstitial lung disease: data from the NEREA Registry. Rheumatology (Oxford). 2020;59:2099–2108.
   PubMed Web of Science ®Google Scholar
• Md Yusof MY, Kabia A, Darby M, et al. Effect of rituximab on the progression of rheumatoid arthritis–related interstitial lung disease: 10 years’ experience at a single centre. Rheumatology. 2017;56:1348–1357.
   PubMed Web of Science ®Google Scholar
• Matteson EL, Bongartz T, Ryu JH, et al. Open-Label, Pilot Study of the safety and clinical effects of rituximab in patients with rheumatoid arthritis-associated interstitial pneumonia. OJRA. 2012;02:53–58.
   Google Scholar
• Smolen JS, Landewé RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020;79:685–699.
   PubMed Web of Science ®Google Scholar
• Singh JA, Saag KG, Bridges SL, et al. American College of Rheumatology Guideline for the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 2015 2016;68:1–25.
   PubMed Web of Science ®Google Scholar
• Sathi N, Chikura B, Kaushik VV, et al. How common is methotrexate pneumonitis? A large prospective study investigates. Clin Rheumatol. 2012;31:79–83.
   PubMed Web of Science ®Google Scholar
• Roubille C, Haraoui B. Interstitial lung diseases induced or exacerbated by DMARDS and biologic agents in rheumatoid arthritis: a systematic literature review. Semin Arthritis Rheum. 2014;43:613–626.
   PubMed Web of Science ®Google Scholar
• Kiely P, Busby AD, Nikiphorou E, et al. Is incident rheumatoid arthritis interstitial lung disease associated with methotrexate treatment? Results from a multivariate analysis in the ERAS and ERAN inception cohorts. BMJ Open. 2019;9:e028466.
   PubMed Web of Science ®Google Scholar
• Juge P-A, Lee JS, and Lau J, et al. Methotrexate and rheumatoid arthritis associated interstitial lung disease. Eur Respir J. 2021;57:2000337 .
   PubMed Web of Science ®Google Scholar
• Rojas-Serrano J, Herrera-Bringas D, Pérez-Román DI, et al. Rheumatoid arthritis-related interstitial lung disease (RA-ILD): methotrexate and the severity of lung disease are associated to prognosis. Clin Rheumatol. 2017;36:1493–1500.
   PubMed Web of Science ®Google Scholar
• Cottin V, Bendstrup E, Bonniaud P, et al. The case of methotrexate and the lung: Dr Jekyll and Mr Hyde. Eur Respir J. 2021;57:2100079.
   PubMedGoogle Scholar
• Scott DL, Wolfe F, Huizinga TWJ. Rheumatoid arthritis. Lancet. 2010;376:1094–1108.
   PubMed Web of Science ®Google Scholar
• Hyrich KL, Lunt M, Watson KD, et al. Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study. Arthritis Rheum. 2007;56:13–20.
   PubMed Web of Science ®Google Scholar
• Nakashita T, Ando K, Kaneko N, et al. Potential risk of TNF inhibitors on the progression of interstitial lung disease in patients with rheumatoid arthritis. BMJ Open. 2014;4:e005615.
   PubMed Web of Science ®Google Scholar
• Manfredi A, Cassone G, Furini F, et al. Tocilizumab therapy in rheumatoid arthritis with interstitial lung disease: a multicentre retrospective study. Intern Med J. 2020;50:1085–1090.
   PubMed Web of Science ®Google Scholar
• Koike T, Harigai M, Inokuma S, et al. Postmarketing surveillance of tocilizumab for rheumatoid arthritis in Japan: interim analysis of 3881 patients. Ann Rheum Dis. 2011;70:2148–2151.
   PubMed Web of Science ®Google Scholar
• Vicente-Rabaneda EF, Atienza-Mateo B, Blanco R, et al. Efficacy and safety of Abatacept in interstitial lung disease of rheumatoid arthritis: a systematic literature review. Autoimmun Rev. 2021;20:102830.
   PubMed Web of Science ®Google Scholar
• Fernández-Díaz C, Castañeda S, Melero-González RB, et al. Abatacept in interstitial lung disease associated with rheumatoid arthritis: national multicenter study of 263 patients. Rheumatology (Oxford). 2020;59:3906–3916.
   PubMed Web of Science ®Google Scholar
• Tardella M, Di Carlo M, Carotti M, et al. Abatacept in rheumatoid arthritis-associated interstitial lung disease: short-term outcomes and predictors of progression. Clin Rheumatol. 2021;40:4861–4867.
   PubMedGoogle Scholar
• Mochizuki T, Ikari K, Yano K, et al. Long-term deterioration of interstitial lung disease in patients with rheumatoid arthritis treated with Abatacept. Mod Rheumatol. 2019;29:413–417.
   PubMed Web of Science ®Google Scholar
• Yun H, Xie F, Delzell E, et al. Comparative risk of hospitalized infection associated with biologic agents in rheumatoid arthritis patients enrolled in medicare. Arthritis Rheumatol. 2016;68:56–66.
   PubMed Web of Science ®Google Scholar
• van Vollenhoven RF, Fleischmann R, Cohen S, et al. Tofacitinib or Adalimumab versus placebo in rheumatoid arthritis. N Engl J Med. 2012;367:508–519.
   PubMed Web of Science ®Google Scholar
• Taylor PC, Keystone EC, van der Heijde D, et al. Baricitinib versus Placebo or Adalimumab in rheumatoid arthritis. N Engl J Med. 2017;376:652–662.
   PubMed Web of Science ®Google Scholar
• Rubbert-Roth A, Enejosa J, Pangan AL, et al. Trial of upadacitinib or abatacept in rheumatoid arthritis. N Engl J Med. 2020;383:1511–1521.
   PubMed Web of Science ®Google Scholar
• Sendo S, Saegusa J, Yamada H, et al. Tofacitinib facilitates the expansion of myeloid-derived suppressor cells and ameliorates interstitial lung disease in SKG mice. Arthritis Res Ther. 2019;21:184.
   PubMed Web of Science ®Google Scholar
• Takanashi S, Kaneko Y, Takeuchi T. Tofacitinib in interstitial lung disease complicated with anti-MDA5 antibody-positive dermatomyositis: a literature review. Mod Rheumatol. 2022:32:231–237.
   PubMedGoogle Scholar
• Vacchi C, Manfredi A, Cassone G, et al. Tofacitinib for the treatment of severe interstitial lung disease related to rheumatoid arthritis. Case Rep Med. 2021;6652845. 2021. DOI:https://doi.org/10.1155/2021/6652845.
   Google Scholar
• Kalyoncu U, Bilgin E, Erden A, et al. Efficacy and safety of tofacitinib in rheumatoid arthritis-associated interstitial lung disease: tReasure real-life data. Clin Exp Rheumatol. 2022.
   Google Scholar
• Sugawara M, Fujieda Y, Noguchi A, et al. Prediction of the intolerance or non-responder to Janus kinase inhibitors in patients with rheumatoid arthritis: a preliminary retrospective study with integrative cluster analysis. Clin Exp Rheumatol. 2021.
   PubMedGoogle Scholar
• Wijsenbeek M, Cottin VN Engl J Med. 2020;383:958–968 .
   PubMed Web of Science ®Google Scholar
• Cottin V, Hirani NA, Hotchkin DL, et al. Presentation, diagnosis and clinical course of the spectrum of progressive-fibrosing interstitial lung diseases. Eur Respir Rev. 2018;27:180076.
   PubMed Web of Science ®Google Scholar
• Wells AU, Brown KK, Flaherty KR, et al. What’s in a name? That which we call IPF, by any other name would act the same. Eur Respir J. 2018;51:1800692.
   PubMed Web of Science ®Google Scholar
• Wijsenbeek M, Kreuter M, Olson A, et al. Progressive fibrosing interstitial lung diseases: current practice in diagnosis and management. Curr Med Res Opin. 2019;35:2015–2024.
   PubMed Web of Science ®Google Scholar
• Jacob J, Hirani N, van Moorsel CHM, et al. Predicting outcomes in rheumatoid arthritis related interstitial lung disease. Eur Respir J. 2019;53:1800869.
   PubMed Web of Science ®Google Scholar
• Kwon BS, Choe J, Chae EJ, et al. Progressive fibrosing interstitial lung disease: prevalence and clinical outcome. Respir Res. 2021;22:282.
   PubMedGoogle Scholar
• Collins BF, Raghu G. Antifibrotic therapy for fibrotic lung disease beyond idiopathic pulmonary fibrosis. Eur Respir Rev. 2019;28:190022.
   PubMedGoogle Scholar
• Distler O, Highland KB, Gahlemann M, et al. Nintedanib for systemic sclerosis–associated interstitial lung disease. N Engl J Med. 2019;380:2518–2528.
   PubMed Web of Science ®Google Scholar
• Flaherty KR, Wells AU, and Cottin V, et al. Nintedanib in progressive fibrosing interstitial lung diseases. N Engl J Med. 2019;381:1718–1727 .
   PubMed Web of Science ®Google Scholar
• Behr J, Prasse A, Kreuter M, et al. Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial. Lancet Respir Med. 2021;9:476–486.
   PubMed Web of Science ®Google Scholar
• Maher TM, Corte TJ, Fischer A, et al. Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Respir Med. 2020;8:147–157.
   PubMed Web of Science ®Google Scholar
• Solomon JJ, Danoff SK, Goldberg HJ, et al. The design and rationale of the trail1 trial: a randomized double-blind phase 2 clinical trial of pirfenidone in rheumatoid arthritis-associated interstitial lung disease. Adv Ther. 2019;36:3279–3287.
   PubMed Web of Science ®Google Scholar
• Flaherty KR, Wells AU, and Cottin V, et al. Nintedanib in progressive interstitial lung diseases: data from the whole INBUILD trial. Eur Respir J. 2022;59:2004538.
   PubMedGoogle Scholar
• Kelly C, Matteson E, Aringer M, et al. OP0124 Effects of nintedanib in patients with progressive fibrosing interstitial lung disease associated with rheumatoid arthritis (RA-ILD) in the inbuild trial. Ann Rheum Dis. 2021;80:69.
   Google Scholar
• Cottin V, Richeldi L, Rosas I, et al. Nintedanib and immunomodulatory therapies in progressive fibrosing interstitial lung diseases. Respir Res. 2021;22:84.
   PubMedGoogle Scholar
• Redente EF, Aguilar MA, Black BP, et al. Nintedanib reduces pulmonary fibrosis in a model of rheumatoid arthritis-associated interstitial lung disease. Am J Physiol Lung Cell Mol Physiol. 2018;314:L998–L1009.
   PubMed Web of Science ®Google Scholar
• Hamblin MJ, Horton MR. Rheumatoid arthritis-associated interstitial lung disease: diagnostic dilemma. Pulm Med.2011 ;2011 :872120.
   PubMedGoogle Scholar
• Dowman L, Hill CJ, May A, et al. Pulmonary rehabilitation for interstitial lung disease. Cochrane Database Syst Rev. 2021;2:CD006322.
   PubMedGoogle Scholar
• Lim RK, Humphreys C, Morisset J, et al. Oxygen in patients with fibrotic interstitial lung disease: an international Delphi survey. Eur Respir J. 2019;54:1900421.
   PubMedGoogle Scholar
• Shweish O, Dronavalli G. Indications for lung transplant referral and listing. J Thorac Dis. 2019;11:S1708–S1720.
   PubMedGoogle Scholar
• Yazdani A, Singer LG, Strand V, et al. Survival and quality of life in rheumatoid arthritis-associated interstitial lung disease after lung transplantation. J Heart Lung Transplant. 2014;33:514–520.
   PubMed Web of Science ®Google Scholar
• Courtwright AM, El-Chemaly S, Dellaripa PF, et al. Survival and outcomes after lung transplantation for non-scleroderma connective tissue-related interstitial lung disease. J Heart Lung Transplant. 2017;36:763–769.
   PubMed Web of Science ®Google Scholar
• Flaherty KR, Brown KK, Wells AU, et al. Design of the PF-ILD trial: a double-blind, randomised, placebo-controlled phase III trial of nintedanib in patients with progressive fibrosing interstitial lung disease. BMJ Open Respir Res. 2017;4:e000212.
   PubMed Web of Science ®Google Scholar